ST. LOUIS, Jan. 14 /PRNewswire-FirstCall/ -- At the Boston Atrial Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: STXS) will showcase three advances in remote magnetic ablation that it believes will enhance the efficiency, performance and versatility of its Niobe(R) Magnetic Navigation System. In booth #917, Stereotaxis will exhibit its new software platform, Navigant 3.0, with the QuikCAS(TM) Cardiodrive(R) System for enhanced remote catheter control and improved EP lab workflow, and its partnered magnetic irrigated catheter, which is now available in Europe.
"Together these three products represent a significant advancement in remote cardiovascular procedures," said Michael P. Kaminski, Stereotaxis President and CEO.
-- The QuikCAS Cardiodrive System remotely advances and retracts the catheter in the patient's heart while the Niobe magnets precisely steer the catheter's distal tip. The QuikCAS advancements provide the clinician with greater responsiveness for enhanced performance, a more ergonomic design and faster set-up for improved workflow.
-- Stereotaxis' partnered magnetic irrigated catheter, now available in Europe, is widely recognized as the gold standard for complex ablations such as ventricular tachycardia and complex left atrial arrhythmias. European clinicians have treated more than 600 patients with the magnetic irrigated catheter, with extremely positive results. Stereotaxis has prepared a monograph of these results and will be highlighting the data at the Symposium.
-- Navigant 3.0 is Stereotaxis' new software platform for its Niobe
Magnetic Navigation System. It provides users with many enhanced features and
new capabilities that simplify and accelerate its use, including automated
registration of the 3D mapping system and calibration of the Cardiodrive
|SOURCE Stereotaxis, Inc.|
Copyright©2009 PR Newswire.
All rights reserved